Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Outlook Therapeutics (OTLK) Revenue (2016 - 2025)

Outlook Therapeutics (OTLK) has disclosed Revenue for 7 consecutive years, with $1.5 million as the latest value for Q2 2025.

  • On a quarterly basis, Revenue changed N/A to $1.5 million in Q2 2025 year-over-year; TTM through Dec 2025 was $1.5 million, a 186.64% increase, with the full-year FY2025 number at $1.4 million, up 144.78% from a year prior.
  • Revenue was $1.5 million for Q2 2025 at Outlook Therapeutics, up from -$443624.0 in the prior quarter.
  • In the past five years, Revenue ranged from a high of $1.5 million in Q2 2025 to a low of $1.5 million in Q2 2025.